Neuren Pharmaceuticals (ASX:NEU)

Neuren Pharmaceuticals is a Melbourne-based drug developer. The company’s lead compound is Trofinetide, for the treatment of two Autism Spectrum Disorders, Rett Syndrome and Fragile X Syndrome. The company has generated favourable Phase 2 data in both these conditions.

7/03/2019 Neuren keeps Rest-of-World rights for Trofinetide

5/12/2018 In Phase 3, priced like Phase 2